Trial · NCT07893678
Virtual Reality to Advance Dementia Care and Quality of Life
NCT07893678, Not applicable, Not yet recruiting, London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Virtual Reality to Advance Dementia Care and Quality of Life. Trials, record NCT07893678. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07893678
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Virtual Reality to Advance Dementia Care and Quality of Life
- NCT number
- NCT07893678
- Status
- Not yet recruiting
- Phases
- Not applicable
- Enrollment
- 10 participants, estimated
- Lead sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
- Conditions
- Dementia, Agitation, Behavioural and Psychological Symptoms of Dementia, Major Neurocognitive Disorder, Agitation Aggression in Dementia
- Interventions
- Supervised Virtual Reality Sessions
- First posted
- 2026-10-26
- Last updated
- 2026-10-26
Source ClinicalTrials.gov
Registered outcomes18
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Recruitment feasibility and recruitment rate | From start of recruitment through completion of enrollment, anticipated up to approximately 14 months | Recruitment flow will be summarized using the numbers and proportions of potentially eligible individuals identified or referred, proceeding to informed consent, meeting formal eligibility criteria, and enrolling. Recruitment rate will be calculated as the number of formally eligible individuals enrolled divided by the total number of formally eligible individuals. |
| Primary | Participant retention rate | From enrollment through the planned end-of-study timepoint, up to approximately 7 weeks per participant | Participant retention rate will be calculated as the proportion of enrolled participants who remain in study follow-up through the planned end-of-study timepoint, whether or not they complete all planned regular VR sessions. Completion of an end-of-study or early-termination assessment will be measured separately. |
| Primary | Intervention initiation rate | From enrollment through the first regular VR intervention session or determination of non-initiation, anticipated within approximately 2 weeks per participant | Intervention initiation rate will be calculated as the proportion of enrolled participants who initiate at least one regular VR intervention session. Familiarization or orientation will not constitute intervention initiation. |
| Primary | Intervention adherence and session completion | During the VR intervention period, up to approximately 6 weeks | Intervention adherence will be calculated among participants who initiate at least one regular VR intervention session as the number of participant-specific planned regular VR sessions completed as tolerated divided by the total number of participant-specific planned regular VR sessions. Participants may have up to 18 planned regular VR sessions over up to six weeks. Familiarization will be excluded from the adherence calculation. |
| Primary | Session-delivery feasibility | During the VR intervention period, up to approximately 6 weeks | Prospectively planned regular VR sessions that are offered but not initiated, stopped early, deferred, or not conducted will be summarized by frequency and reason. Reasons may include participant refusal or unavailability, clinical or safety considerations, discharge or transfer, medication-related timing, staffing or workflow limitations, infection-prevention requirements, or device and technical problems. |
| Primary | Intervention completion and disposition | From enrollment through end-of-study or early termination, up to approximately 7 weeks per participant | The numbers and proportions of enrolled participants who complete the planned VR intervention period, permanently discontinue VR before the planned end of the intervention period, or terminate study participation early will be summarized, together with the reasons. |
| Primary | Intervention tolerability | During the VR intervention period, up to approximately 6 weeks | Intervention tolerability will be summarized using the number and proportion of regular VR sessions associated with intolerance or early stopping, the types and outcomes of tolerability events, and the number and proportion of intervention-exposed participants who permanently discontinue VR because of VR-related intolerance or adverse effects. |
| Primary | Safety and session-level tolerability events | From informed consent through end-of-study or early termination, up to approximately 7 weeks per enrolled participant | Adverse events and serious adverse events will be summarized by frequency, type, severity, seriousness, relationship to VR or study procedures, action taken, and outcome. Session-level intolerance or tolerability events and other safety concerns associated with VR exposure or study participation will also be summarized descriptively. |
| Primary | Staff acceptability, appropriateness, usability, implementation feasibility, perceived workload and workflow burden, and workflow integration | From completion of facilitator training/orientation through the end of relevant staff involvement or intervention delivery, through study completion, anticipated up to approximately 15 months | Staff implementation outcomes will be assessed through two complementary staff-feedback pathways using three study-specific questionnaires: matched pre- and post-implementation questionnaires for appropriately trained and PI/Site PI-delegated VR facilitators, and a separate one-time questionnaire for eligible frontline care staff with relevant direct experience who are not acting as formal VR facilitators. Outcomes include acceptability, appropriateness, usability, implementation feasibility, perceived benefits and concerns, training and support, workload and workflow fit, barriers, facilitators, sustainability, and recommendations for future implementation. |
| Primary | Final-assessment completion rate | From enrollment through end-of-study or early termination, up to approximately 7 weeks per participant | Final-assessment completion rate will be calculated as the proportion of enrolled participants who complete an end-of-study or early-termination assessment. This outcome will be reported separately from participant retention. |
1 to 10 of 18Source ClinicalTrials.gov
See all 18 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers7
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07893678
GET https://conductscience.org/api/trials/v1/NCT07893678/registered